Pendal Group’s Idexx Laboratories IDXX Stock Holding History

Pendal Group’s Portfolio IDXX Stock Details IDXX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-9,667	Closed	-$1.56M	–	468
2017 Q2	$1.56M	Buy	+9,667	New	+$1.57M	0.02%	247

Other funds holding IDXX

Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Pendal Group's IDXX Position: Q3 2017 in Review

Pendal Group sold out of Idexx Laboratories (IDXX) in Q3 2017, closing a stake of 9,667 shares — an estimated $1.56M sold.

Pendal Group first reported a position in IDXX in Q2 2017 and held it in 1 quarter. The position peaked at $1.56M in Q2 2017. 573 funds tracked by Wall St. Rank hold IDXX as of Q3 2017.

Pendal Group reported no remaining Idexx Laboratories position as of Q3 2017 after selling out during the quarter.
Pendal Group sold 9,667 Idexx Laboratories shares in Q3 2017, an estimated $1.56M.
Pendal Group first reported a position in Idexx Laboratories in Q2 2017 and held it in 1 quarter.
Pendal Group's Idexx Laboratories position peaked at $1.56M in Q2 2017.
573 funds tracked by Wall St. Rank held Idexx Laboratories as of Q3 2017.

Based on Pendal Group's 13F filing for Q3 2017, filed 1 Nov 2017.